| Nome |
# |
|
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)., file e27ce426-eda7-2581-e053-d805fe0acbaa
|
478
|
|
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients., file e27ce429-f428-2581-e053-d805fe0acbaa
|
335
|
|
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib., file e27ce42a-a912-2581-e053-d805fe0acbaa
|
298
|
|
BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation, file e27ce42a-4ddf-2581-e053-d805fe0acbaa
|
188
|
|
The choice of first-line chronic myelogenous leukemia treatment, file e27ce42a-98df-2581-e053-d805fe0acbaa
|
173
|
|
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors., file e27ce42a-9005-2581-e053-d805fe0acbaa
|
169
|
|
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH, file e27ce428-c072-2581-e053-d805fe0acbaa
|
165
|
|
Recommendations for the Management of CML in the Era of Second-Generation TKIs, file e27ce42a-d161-2581-e053-d805fe0acbaa
|
156
|
|
Milestones and Monitoring, file e27ce427-1d78-2581-e053-d805fe0acbaa
|
151
|
|
Deferasirox-dependent iron chelation enhances mitochondrial dysfunction and restores p53 signaling by stabilization of p53 family members in leukemic cells, file e27ce430-ba33-2581-e053-d805fe0acbaa
|
151
|
|
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity, file e27ce431-c41d-2581-e053-d805fe0acbaa
|
139
|
|
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome, file e27ce42a-1d2a-2581-e053-d805fe0acbaa
|
136
|
|
Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1, file e27ce431-2566-2581-e053-d805fe0acbaa
|
132
|
|
Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways, file e27ce42e-0b48-2581-e053-d805fe0acbaa
|
131
|
|
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia, file e27ce42a-b5ef-2581-e053-d805fe0acbaa
|
130
|
|
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia, file e27ce42a-6844-2581-e053-d805fe0acbaa
|
119
|
|
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report, file e27ce42d-4982-2581-e053-d805fe0acbaa
|
117
|
|
Development and targeted use of nilotinib in chronic myeloid leukemia., file e27ce42a-9aad-2581-e053-d805fe0acbaa
|
115
|
|
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP, file e27ce42f-5279-2581-e053-d805fe0acbaa
|
106
|
|
Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe., file e27ce42f-a4d9-2581-e053-d805fe0acbaa
|
101
|
|
Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?, file e27ce42e-1c48-2581-e053-d805fe0acbaa
|
97
|
|
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR, file e27ce430-8e47-2581-e053-d805fe0acbaa
|
97
|
|
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia, file e27ce42c-18ce-2581-e053-d805fe0acbaa
|
95
|
|
Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells, file e27ce42e-93f2-2581-e053-d805fe0acbaa
|
90
|
|
Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts, file e27ce42f-c6f4-2581-e053-d805fe0acbaa
|
89
|
|
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission, file e27ce42e-1c42-2581-e053-d805fe0acbaa
|
88
|
|
Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?, file e27ce42d-fd7e-2581-e053-d805fe0acbaa
|
87
|
|
Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia, file e27ce42f-8fea-2581-e053-d805fe0acbaa
|
86
|
|
Corticosteroids can reverse severe imatinib-induced hepatotoxicity, file e27ce426-9ed4-2581-e053-d805fe0acbaa
|
76
|
|
The Q-LAMP method represents a valid and rapid alternative for the detection of the BCR-ABL1 rearrangement in Philadelphia-positive Leukemias, file e27ce42f-5632-2581-e053-d805fe0acbaa
|
66
|
|
Philadelphia-positive lymphoblastic lymphoma: A case report and review of the literature, file e27ce42f-5840-2581-e053-d805fe0acbaa
|
63
|
|
Treatment-free remission in chronic myeloid leukemia harboring atypical BCRABL1 transcripts, file e27ce430-e25d-2581-e053-d805fe0acbaa
|
58
|
|
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience, file e27ce432-19f0-2581-e053-d805fe0acbaa
|
55
|
|
To Swab or Not to Swab? The Lesson Learned in Italy in the Early Stage of the COVID-19 Pandemic, file e27ce432-1c39-2581-e053-d805fe0acbaa
|
54
|
|
Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (Thermofisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia, file e27ce432-1025-2581-e053-d805fe0acbaa
|
48
|
|
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation, file e27ce432-8806-2581-e053-d805fe0acbaa
|
48
|
|
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice, file e27ce430-0dcb-2581-e053-d805fe0acbaa
|
45
|
|
Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?, file e27ce433-35d6-2581-e053-d805fe0acbaa
|
42
|
|
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis, file e27ce435-4272-2581-e053-d805fe0acbaa
|
42
|
|
Differences among young adults, adults and elderly chronic myeloid leukemia patients., file e27ce42a-c137-2581-e053-d805fe0acbaa
|
38
|
|
Detection of SF3B1 p.Lys700Glu Mutation by PNA-PCR Clamping in Myelodysplastic Syndromes and Myeloproliferative Neoplasms, file e27ce434-b1d2-2581-e053-d805fe0acbaa
|
20
|
|
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice, file e27ce432-4903-2581-e053-d805fe0acbaa
|
11
|
|
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies, file e27ce432-cc42-2581-e053-d805fe0acbaa
|
11
|
|
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib, file e27ce42e-1c46-2581-e053-d805fe0acbaa
|
10
|
|
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study, file e27ce435-4274-2581-e053-d805fe0acbaa
|
8
|
|
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia, file e27ce428-c622-2581-e053-d805fe0acbaa
|
6
|
|
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients., file e27ce429-f91b-2581-e053-d805fe0acbaa
|
5
|
|
Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor, file e27ce42a-e9c3-2581-e053-d805fe0acbaa
|
5
|
|
Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia, file e27ce42f-a1ee-2581-e053-d805fe0acbaa
|
5
|
|
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study), file e27ce435-4520-2581-e053-d805fe0acbaa
|
5
|
|
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study, file e27ce435-5c85-2581-e053-d805fe0acbaa
|
5
|
|
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report, file e27ce435-7bc0-2581-e053-d805fe0acbaa
|
5
|
|
Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy, file 73cf78fd-6c42-4afe-938a-38e7651482f7
|
4
|
|
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib., file e27ce42a-c8ab-2581-e053-d805fe0acbaa
|
4
|
|
Ponatinib for chronic myeloid leukaemia: Future perspectives, file e27ce42a-ed78-2581-e053-d805fe0acbaa
|
4
|
|
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia., file e27ce42a-a65a-2581-e053-d805fe0acbaa
|
3
|
|
Practical monitoring of chronic myelogenous leukemia: when to change treatment, file e27ce42a-c3cc-2581-e053-d805fe0acbaa
|
3
|
|
Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells, file 6e973927-beaf-4ada-8416-48166793ac8d
|
2
|
|
BCR-ABL1 mutation not equal ponatinib resistance, file e27ce42a-8ddc-2581-e053-d805fe0acbaa
|
2
|
|
Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?, file e27ce42a-9c1d-2581-e053-d805fe0acbaa
|
2
|
|
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib., file e27ce42a-a662-2581-e053-d805fe0acbaa
|
2
|
|
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study., file e27ce42a-ac7f-2581-e053-d805fe0acbaa
|
2
|
|
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase., file e27ce42a-ecc8-2581-e053-d805fe0acbaa
|
2
|
|
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)., file e27ce42a-ee0b-2581-e053-d805fe0acbaa
|
2
|
|
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia, file e27ce42b-d340-2581-e053-d805fe0acbaa
|
2
|
|
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome, file e27ce42e-1c44-2581-e053-d805fe0acbaa
|
2
|
|
Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes, file e27ce42f-7884-2581-e053-d805fe0acbaa
|
2
|
|
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study, file e27ce431-0c1e-2581-e053-d805fe0acbaa
|
2
|
|
Kinase-inhibitor–insensitive cancer stem cells in chronic myeloid leukemia, file e27ce42a-894e-2581-e053-d805fe0acbaa
|
1
|
|
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia., file e27ce42a-a41a-2581-e053-d805fe0acbaa
|
1
|
|
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia., file e27ce42a-b98f-2581-e053-d805fe0acbaa
|
1
|
|
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia., file e27ce42a-beec-2581-e053-d805fe0acbaa
|
1
|
|
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib., file e27ce42a-c2e9-2581-e053-d805fe0acbaa
|
1
|
|
Concomitant occurrence of BCR-ABL and JAK2V617F mutation., file e27ce42a-c2eb-2581-e053-d805fe0acbaa
|
1
|
|
Chronic myeloid leukemia: state of the art in 2012, file e27ce42a-c3ce-2581-e053-d805fe0acbaa
|
1
|
|
Update on emerging treatments for chronic myeloid leukemia, file e27ce42a-c767-2581-e053-d805fe0acbaa
|
1
|
|
Second-Generation Tyrosine Kinase Inhibitors Can Induce Complete Molecular Response in Ph-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplant, file e27ce42a-de85-2581-e053-d805fe0acbaa
|
1
|
|
null, file e27ce42a-efc0-2581-e053-d805fe0acbaa
|
1
|
|
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series, file e27ce42e-1da5-2581-e053-d805fe0acbaa
|
1
|
|
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline, file e27ce42f-7508-2581-e053-d805fe0acbaa
|
1
|
| Totale |
5.002 |